In this podcast, Patricia K. Coyle, MD, discusses anticipated developments in the field of multiple sclerosis this year, including clinical trial data, COVID-19 vaccination, wearable devices, and more. A full transcript is provided.
Farrah Mateen, MD, PhD, from Harvard Medical School and Massachusetts General Hospital in Boston, answers our questions about current recommendations for COVID-19 vaccination among patients with multiple sclerosis, as well as key areas of future research.
In this podcast, Dr Coyle discusses the "final word" on myelin oligodendrocyte glycoprotein-mediated disease in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting. A full transcript is provided.
Prodromes are well documented for neurodegenerative disorders such as Parkinson disease and Alzheimer disease, and there are increasing data for a multiple sclerosis (MS) prodrome, writes Patricia K. Coyle, MD, from Stony Brook University. In this commentary, Dr Coyle reviews evidence of prodromal MS.
In this podcast, Dr Coyle discusses the "final word" on strategies to promote remyelination in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.
In this video, Amit Bar-Or, MD, FRCPC, gives an overview of encouraging findings regarding the long-term safety of ozanimod for relapsing forms of multiple sclerosis.
Exploring the Transformation of Diffusely Abnormal White Matter Regions into Focal White Matter Lesions in SPMS
Mahsa Dadar, PhD, answers our questions about her new study that suggested diffusely abnormal white matter regions in the brain evolve into focal white matter lesions over time in secondary progressive multiple sclerosis, which in turn may be associated with clinical disease progression.
Shiv Saidha, MBBCh, answered our questions about his study, which suggests that elevated body mass index may be associated with accelerated ganglion cell + inner plexiform layer atrophy in the absence of overt metabolic comorbidities among patients with multiple sclerosis.
In this video, Amit Bar-Or, MD, FRCPC, discusses new long-term data that show a favorable safety profile over time with the use of ozanimod among patients with relapsing forms of multiple sclerosis.
In this podcast, Dr Coyle discusses the "final word" on neuromyelitis optica spectrum disorder in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.